GlassScriptPhysician profile
Michelle Henry
NPI 1154569275
$459,797.45
in general payments reported to CMS, 2019-2025
27 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $49K · 2021: $77K · 2022: $72K · 2023: $130K · 2024: $53K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $103K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $13K · Food and Beverage: $7,080 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $103,424.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,270.00 |
| Travel and Lodging | $13,055.03 |
| Food and Beverage | $7,080.25 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $208,024.53 | 2019-2022 | |
| Abbvie INC. | $160,000.01 | 2022-2025 | |
| Galderma Laboratories, L.P. | $30,948.82 | 2019-2025 | Aklief, Oracea, Epsolay |
| Merz North America, INC. | $27,428.90 | 2019-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $11,554.98 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10,654.73 | 2021-2025 | Cabtreo, Jublia |
| Solta Medical, A Division of Bausch Health US, LLC | $3,505.58 | 2020-2025 | |
| Epi Health, LLC | $2,494.74 | 2022 | |
| Endo Pharmaceuticals INC. | $1,130.32 | 2019 | |
| Botanix Sb INC | $1,057.62 | 2025 | Sofdra |
| Intuitive Surgical, INC. | $1,042.78 | 2019 | |
| Sun Pharmaceutical Industries INC. | $504.03 | 2020-2025 | Absorica Ld, Winlevi |
| Revance Therapeutics, INC. | $202.93 | 2024 | Daxxify |
| Journey Medical Corporation | $191.49 | 2022-2025 | |
| Pfizer INC. | $188.77 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $155.66 | 2024-2025 | Opzelura |
| Amgen INC. | $154.99 | 2022-2025 | Otezla, Otezla |
| Genentech, INC. | $146.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $74.54 | 2025 | Libtayo |
| Janssen Biotech, INC. | $69.57 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $67.53 | 2023-2024 | Zoryve |
| Genzyme Corporation | $46.22 | 2023 | |
| Mayne Pharma Commercial LLC | $44.69 | 2025 | |
| Almirall LLC | $41.39 | 2022 | |
| Organon LLC | $27.11 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.45 | 2025 | Sotyktu |
| Lilly USA, LLC | $17.93 | 2023 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.